Navigation Links
Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012
Date:7/28/2011

ent by a former competitor that they were exiting the bulking market.

"Our fiscal first quarter reflects the increasing adoption and utilization of our Urgent PC System, as well as strength in sales of Macroplastique as we aggressively pursue a short-term opportunity to capture market share," said David Kaysen, President and CEO of Uroplasty, Inc.  "Acceptance of Urgent PC is growing, as demonstrated by the increasing number of active customers.  The number of lead set boxes sold increased from 1,668 in the fiscal fourth quarter of 2011 to 1,985 in the fiscal first quarter of 2012."

"Last week we announced that Health Care Service Corporation (HCSC), the second largest Blue Cross Blue Shield affiliate and the fourth largest private payer in the U.S., will cover PTNS therapy using the Urgent PC Neuromodulation System beginning August 1, 2011.  HCSC covers approximately 13 million lives in Texas, Illinois, New Mexico and Oklahoma," Mr. Kaysen indicated.  "We were also pleased that Blue Cross Blue Shield of Nebraska, covering approximately 668,000 lives, initiated coverage beginning May 18, 2011.  This brings the total number of persons covered by insurance that provides reimbursement for PTNS treatments, including both Medicare coverage and private payer coverage, to approximately 115 million."

"Sales of Macroplastique, particularly in the U.S., were a significant factor in our sales growth during the quarter.  With the exit of a major competitor, we have a short window of opportunity to present the benefits of our product and gain new customers for Macroplastique.  Our efforts during the quarter were very successful and established a new sales record for Macroplastique.  We anticipate continued growth in sales of this product in the U.S. over the next few quarters," continued Mr. Kaysen.

Net sales to customers outside of the U.S. for the fiscal first quarter ended June 30, 2011 totaled $1.8 million,
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Uroplasty to Issue First Quarter 2012 Financial Results on July 28, 2011
2. Two Additional Private Payers Provide Coverage for Posterior Tibial Nerve Stimulation Delivered Using the Uroplasty Urgent® PC Neuromodulation System
3. Uroplasty on Preliminary List of Additions to Russell 3000® and Russell Global® Indexes
4. Uroplastys Dave Kaysen to Ring NASDAQ Closing Bell
5. Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011
6. Uroplasty to Present at the JMP Securities Research Conference
7. Clinical Studies Results of Uroplasty Products Scheduled for Presentation at Three Professional Meetings
8. Uroplasty Announces Expanded Insurance Coverage of Posterior Tibial Nerve Stimulation (PTNS) Delivered Using the Urgent® PC Neuromodulation System
9. Uroplasty to Present at ROTH Capital Partners 23rd Annual OC Growth Stock Conference
10. Uroplasty Reports Financial Results for the Third Quarter FY2011
11. Uroplasty to Issue Third Quarter 2011 Results on January 27, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... and LONDON , Nov. 25, ... AstraZeneca (NYSE: AZN ) today announced that AMAGINE-2 ... doses of brodalumab in more than 1,800 patients with moderate-to-severe ... Stelara ® (ustekinumab) and placebo at week 12. Brodalumab ... analysis group were each shown to be superior to Stelara ...
(Date:11/26/2014)... China, Nov. 26, 2014 China Nepstar Chain ... "Company"), a leading retail drugstore chain in China based ... its unaudited financial results for the third quarter ended September ... 30, 2014: , Same store sales increased by ... , Revenue increased by 8.1% to RMB738.3 million (US$120.3 million) ...
(Date:11/24/2014)... 24, 2014 Luoxis Diagnostics, Inc., a ... today announced the presentation of three clinical and ... a broadly applicable and robust research tool capable ... in response to injury, illness, or stress.  In ... with Luoxis, academic and pharmaceutical research partners, RedoxSYS ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 11Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5
... According to Millennium Research Group (MRG), the global authority ... device market was valued at $41 million in 2010, ... awareness of health issues surrounding obesity, coupled with an ... will drive significant growth in the gastric band market ...
... 28 Decision Resources, one of the world,s ... healthcare issues, finds that oncologists will be the ... specialties because of their lower clinical trial requirements. ... Physician Perspectives on Biosimilar G-CSFs and ...
Cached Medicine Technology:While Ethicon Endo-Surgery and Allergan Remain Front-Runners in the $41 Million Gastric Band Market, Other Competitors Battle for Third Place, According to Millennium Research Group 2Oncologists Will Be More Aggressive In Adopting Biosimilars Compared With Other Specialties 2
(Date:11/26/2014)... (PRWEB) November 26, 2014 The family ... $100,000 to the Mesothelioma Applied Research Foundation (Meso Foundation), ... Meso Foundation’s Patient Travel Grant Program . The ... is to create grant partnerships with organizations that can ... , Mr. Schulze is the founder and chairman emeritus ...
(Date:11/26/2014)... November 26, 2014 The American ... the Association’s new director of meetings and conferences. ... annual meeting, special events and conferences. , ... this post,” said AAA Executive Director Ed Liebow. ... enthusiasm and energy. She was recognized in January ...
(Date:11/26/2014)... Washington, DC (PRWEB) November 26, 2014 ... Inc.’s (AIS) independently published The AIS Report on Blue ... Inc. and WellPoint, Inc. on the varied strategies the ... costs and improve compliance with treatments for sleep apnea, ... The sleep disorder, because it’s linked to increased rates ...
(Date:11/26/2014)... Santa Rosa, California (PRWEB) November 26, 2014 ... be making never before seen reductions in prices of ... and Liposomal Vitamin D3 . Discounts ... only. , GI for Life’s proprietary ColoVite ... leading board-certified gastroenterologists to promote colon health. One easy-to-take ...
(Date:11/26/2014)... Anthropologists have identified concrete recommendations that ... Ebola, improve international support, and pave the way ... Africa. , The report, “Strengthening West African ... Insights,” will be made public during a press ... Fri., Dec. 5, 11 a.m., at the AAA ...
Breaking Medicine News(10 mins):Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 2Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 3Health News:American Anthropological Association Appoints New Director of Meetings and Conferences: Ushma Suvarnakar 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 3
... team led by scientists at Cold Spring Harbor Laboratory (CSHL) ... through thousands of candidate hairpin-shaped RNA molecules at a time ... the activity of a target gene. This accomplishment will now ... cellular mechanism that has already been co-opted by scientists for ...
... Foundation has awarded four new grants to help improve ... hepatitis C (HCV) in China and India. The grants ... commitment to reducing hepatitis-related health disparities in Asia to ... grant recipients were announced at the Asian Pacific Association ...
... the U.S. with hepatitis C virus (HCV) are twice as ... without the disease. In fact researchers found only a third ... remaining are either uninsured or not candidates for therapy due ... the March issue of Hepatology , a peer-reviewed journal ...
... in Spanish . , When the family doctor is ... the management of their health problem, especially when it is a ... expectations of their family doctor "listening to them, keeping them informed ... This was the conclusion drawn of a study recently conducted by ...
... study accepted for publication in The Endocrine Society,s Journal ... with fatty liver were five times more likely to develop ... risk seemed to occur regardless of the patient,s fasting insulin ... In recent years, fatty liver has become more appreciated ...
... have often referred to ultrasound technology as the "stethoscope of ... it will one day be as common at the bedside ... a new report in The New England Journal of ... "Current Concepts" article by Yale School of Medicine clinicians Christopher ...
Cached Medicine News:Health News:New method powerfully boosts efficiency of RNA interference (RNAi) in shutting down genes 2Health News:New method powerfully boosts efficiency of RNA interference (RNAi) in shutting down genes 3Health News:Bristol-Myers Squibb Foundation awards nearly $1M to HBV, HCV awareness, prevention and care 2Health News:Bristol-Myers Squibb Foundation awards nearly $1M to HBV, HCV awareness, prevention and care 3Health News:Lack of health insurance limits hepatitis C patients' access to latest antiviral therapy 2Health News:When the doctor is a woman, patients expect them to be involved in decision making 2Health News:Fatty liver may herald impending Type 2 diabetes 2Health News:Bedside ultrasound becomes a reality 2
The ImagingPlanet 70 mm surgical microscope video adapter: Superior optical quality and precise engineering make this 70 mm focal length adapter an excellent decision for use with your Leica surgica...
The ImagingPlanet 80 mm surgical microscope video adapter: superior optical quality and precise engineering make this 80 mm focal length adapter an excellent decision for use with your Leica surgical...
The ImagingPlanet 55 mm Surgical Microscope Adapter. Superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Zeiss surgical micro...
... Archive Manage and Retrieve ... Optronics DVMR- office, the first ... for the physician's office environment. ... variety of high-resolution cameras for ...
Medicine Products: